Evidence map›Paper›PMID 40575250›Full record

ArticleMDM policy & practice

A Cost-Effectiveness Analysis of Diffuse Large B-Cell Lymphoma Treatment Pathways in the United States.

Anik R Patel, Bradley Kievit, Ken Hasegawa, Markqayne Ray, Rishika Sharma, Sarahmaria Hofmann, Rob Blissett, Frederick L Locke

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in MDM policy & practice. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Anik R PatelKite, a Gilead Company, Santa Monica, CA, USA.
Bradley KievitMaple Health Group, New York, USA.ORCID https://orcid.org/0009-0008-0180-8972
Ken HasegawaKite, a Gilead Company, Santa Monica, CA, USA.
Markqayne RayKite, a Gilead Company, Santa Monica, CA, USA.
Rishika SharmaMaple Health Group, New York, USA.
Sarahmaria HofmannMaple Health Group, New York, USA.
Rob BlissettMaple Health Group, New York, USA.
Frederick L LockeH. Lee Moffitt Cancer Center & Research Institute, Tampa, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Highlights: This study investigated whether axicabtagene ciloleucel (axi-cel) is cost-effective in second-line (2L) and third-line (3L) treatment sequences in the current relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) treatment paradigm.Using a novel treatment sequencing model, axi-cel was found to be cost-effective in both 2L treatment sequences and in direct comparisons with 3L bispecific T-cell antibodies.These findings suggest that axi-cel is a cost-effective treatment for R/R DLBCL regardless of treatment line positioning.

Indexed as

axicabtagene ciloleucelbispecific antibody therapyCAR T-cell therapycost-effectivenessepcoritamabglofitamablymphomamixture cure modelsurvival analysis

Identifiers

PMID40575250
PMCPMC12198509

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.